References
[1] Moschetti, K., Cummings, P. L., Sorvillo, F., and Kuo, T. (2012) Burden of Alzheimer’s disease-related mortality in the United States, 1999-2008, Journal of the American Geriatrics Society 60, 1509-1514.
[2] James, B. D., Leurgans, S. E., Hebert, L. E., Scherr, P. A., Yaffe, K., and Bennett, D. A. (2014) Contribution of Alzheimer disease to mortality in the United States, Neurology 82, 1045-1050.
[3] Goure, W. F., Krafft, G. A., Jerecic, J., and Hefti, F. (2014) Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics, Alzheimers Res Ther 6 , 42.
[4] De Strooper, B., Vassar, R., and Golde, T. (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease, Nat Rev Neurol 6 , 99-107.
[5] Gardberg, A. S., Dice, L. T., Ou, S., Rich, R. L., Helmbrecht, E., Ko, J., Wetzel, R., Myszka, D. G., Patterson, P. H., and Dealwis, C. (2007) Molecular basis for passive immunotherapy of Alzheimer’s disease, Proc Natl Acad Sci U S A 104 , 15659-15664.
[6] Cummings, J. L., Morstorf, T., and Zhong, K. (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures, Alzheimers Res Ther 6 , 37.
[7] De Strooper, B. (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process, Physiological reviews 90 , 465-494.
[8] Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li, Q. X., Laws, S. M., Taddei, K., Rainey-Smith, S., Robertson, J. S., Vandijck, M., Vanderstichele, H., Barnham, K. J., Ellis, K. A., Szoeke, C., Macaulay, L., Rowe, C. C., Villemagne, V. L., Ames, D., Martins, R. N., Bush, A. I., Masters, C. L., and group, A. r. (2014) Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease, Alzheimers Dement 10, 53-61.
[9] Walti, M. A., Ravotti, F., Arai, H., Glabe, C. G., Wall, J. S., Bockmann, A., Guntert, P., Meier, B. H., and Riek, R. (2016) Atomic-resolution structure of a disease-relevant Abeta(1-42) amyloid fibril, Proc Natl Acad Sci U S A 113, E4976-4984.
[10] Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B., and Teplow, D. B. (2003) Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways, Proc Natl Acad Sci U S A 100 , 330-335.
[11] Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., Wada, Y., Yoshioka, E., Nishizaki, T., Watanabe, Y., and Mori, H. (2008) A new amyloid β variant favoring oligomerization in Alzheimer’s-type dementia, Ann Neurol 63 , 3773-3787.
[12] Wakutani, Y., Watanabe, K., Adachi, Y., Wada-Isoe, K., Urakami, K., Ninomiya, H., Saido, T. C., Hashimoto, T., Iwatsubo, T., and Nakashima, K. (2004) Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer’s disease, J Neurol Neurosurg Psychiatry 75, 1039-1042.
[13] Kamino, K., Sato, S., Sakaki, Y., Yoshiiwa, A., Nishiwaki, Y., Takeda, M., Tanabe, H., Nishimura, T., Ii, K., Stgeorgehyslop, P. H., Miki, T., and Ogihara, T. (1996) Three Different Mutations Of Presenilin 1 Gene In Early-Onset Alzheimers Disease Families, Neuroscience Letters 208, 195-198.
[14] Grabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G. W., and Greenberg, S. M. (2001) Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy, Annals of Neurology 49 , 697-705.
[15] Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., Naslund, J., and Lannfelt, L. (2001) The ’Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation, Nat Neurosci 4, 887-893.
[16] Kamino, K., Orr, H. T., Payami, H., Wijsman, E. M., Alonso, E., Pulst, S. M., Anderson, L., O’dahl, S., Nemens, E., White, J. A., Sadovnick, A. D., Ball, M. J., Kayue, J., Warren, A., McInnis, M., Antonarakis, S. T., Korenberg, J. R., Sharma, V., Kukull, W., Larson, E., Heston, L. L., Martin, G. M., Bird, T. D., and Schellenberg, G. D. (1992) Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region, American Journal of Human Genetics 51, 998-1014.
[17] Tagliavini, F., Rossi, G., Padovani, A., Magoni, M., Andora, G., Sgarzi, M., Bizzi, A., Savioardo, M., Carella, F., Morbin, M., Giaccone, G., and Bugiani, O. (1999) A new βPP mutation related to hereditary cerebral hemorrhage, Alzheimer’s Reports 2 (Suppl.), S28.
[18] Van Broeckhoven, C., Haan, J., Bakker, E., Hardy, J. A., Van Hul, W., Wehnert, A., Vegter-Van der Vlis, M., and Roos, R. A. (1990) Amyloid β protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch), Science 248, 1120-1122.
[19] Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T., Luyendijk, W., and Frangione, B. (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type, Science 248, 1124-1126.
[20] Hendriks, L., van Duijn, C. M., Cras, P., Cruts, M., Van Hul, W., van Harskamp, F., Warren, A., McInnis, M. G., Antonarakis, S. E., Martin, J. J., Hofman, A., and Van Broeckhoven, C. (1992) Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the b-amyloid precursor protein gene, Nature Genetics 1, 218-221.
[21] Janssen, J. C., Beck, J. A., Campbell, T. A., Dickinson, A., Fox, N. C., Harvey, R. J., Houlden, H., Rossor, M. N., and Collinge, J. (2003) Early onset familial Alzheimer’s disease: Mutation frequency in 31 families, Neurology 60, 235-239.
[22] Di Fede, G., Catania, M., Morbin, M., Rossi, G., Suardi, S., Mazzoleni, G., Merlin, M., Giovagnoli, A. R., Prioni, S., Erbetta, A., Falcone, C., Gobbi, M., Colombo, L., Bastone, A., Beeg, M., Manzoni, C., Francescucci, B., Spagnoli, A., Cantù, L., Del Favero, E., Levy, E., Salmona, M., and Tagliavini, F. (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis, Science 323 , 1473.
[23] Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jonsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., and Stefansson, K. (2012) A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline, Nature 488, 96-99.
[24] Rothemund, S., Beyermann, M., Krause, E., Krause, G., Bienert, M., Hodges, R. S., Sykes, B. D., and Sonnichsen, F. D. (1995) Structure effects of double D-amino acid replacements: a nuclear magnetic resonance and circular dichroism study using amphipathic model helices, Biochemistry 34 , 12954-12962.
[25] Krause, E., Beyermann, M., Dathe, M., Rothemund, S., and Bienert, M. (1995) Location of an amphipathic alpha-helix in peptides using reversed-phase HPLC retention behavior of D-amino acid analogs, Analytical chemistry 67 , 252-258.
[26] Wieprecht, T., Dathe, M., Schumann, M., Krause, E., Beyermann, M., and Bienert, M. (1996) Conformational and functional study of magainin 2 in model membrane environments using the new approach of systematic double-D-amino acid replacement, Biochemistry 35 , 10844-10853.
[27] Raskatov, J., and Teplow, D. (2017) Using chirality to probe the structure and function of disordered proteins, submitted.
[28] Warner, C. J., Dutta, S., Foley, A. R., and Raskatov, J. A. (2016) Introduction of d-Glutamate at a Critical Residue of Abeta42 Stabilizes a Prefibrillary Aggregate with Enhanced Toxicity, Chemistry 22 , 11967-11970.
[29] Kaneko, I., Morimoto, K., and Kubo, T. (2001) Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments, Neuroscience 104, 1003-1011.
[30] Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., and Teplow, D. B. (1997) Amyloid β-protein fibrillogenesis: detection of a protofibrillar intermediate, J Biol Chem 272, 22364-22372.
[31] Bitan, G., Lomakin, A., and Teplow, D. B. (2001) Amyloid β-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins, J Biol Chem 276 , 35176-35184.
[32] Urbanc, B., Cruz, L., Yun, S., Buldyrev, S. V., Bitan, G., Teplow, D. B., and Stanley, H. E. (2004) In silico study of amyloid β-protein folding and oligomerization, Proc Natl Acad Sci U S A 101 , 17345-17350.
[33] LeVine, H. (1993) Thioflavine T interaction with synthetic Alzheimer’s disease β-amyloid peptides: detection of amyloid aggregation in solution, Protein Sci 2, 404-410.
[34] LeVine, H. (1999) Quantification of β-sheet amyloid fibril structures with thioflavin T, Methods Enzymol 309, 274-284.
[35] Naiki, H., and Nakakuki, K. (1996) First-order kinetic model of Alzheimer’s β-amyloid fibril extension in vitro, Lab Invest 74 , 374-383.
[36] Kirkitadze, M. D., Condron, M. M., and Teplow, D. B. (2001) Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis, J Mol Biol 312, 1103-1119.
[37] Barrow, C. J., Yasuda, A., Kenny, P. T., and Zagorski, M. G. (1992) Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer’s disease. Analysis of circular dichroism spectra, J Mol Biol 225, 1075-1093.
[38] Teplow, D. B. (2006) Preparation of amyloid β-protein for structural and functional studies, Methods Enzymol 413, 20-33.
[39] Ono, K., Condron, M. M., and Teplow, D. B. (2009) Structure-neurotoxicity relationships of amyloid β-protein oligomers, Proc Natl Acad Sci U S A 106 , 14745-14750.
[40] Baumketner, A., Bernstein, S. L., Wyttenbach, T., Lazo, N. D., Teplow, D. B., Bowers, M. T., and Shea, J. E. (2006) Structure of the 21-30 fragment of amyloid β-protein, Protein Sci 15, 1239-1247.
[41] Lazo, N. D., Grant, M. A., Condron, M. C., Rigby, A. C., and Teplow, D. B. (2005) On the nucleation of amyloid β-protein monomer folding, Protein Sci 14, 1581-1596.
[42] Roychaudhuri, R., Yang, M., Deshpande, A., Cole, G. M., Frautschy, S., Lomakin, A., Benedek, G. B., and Teplow, D. B. (2013) C-terminal turn stability determines assembly differences between Aβ40 and Aβ42, J Mol Biol 425, 292-308.
[43] Gessel, M. M., Wu, C., Li, H., Bitan, G., Shea, J. E., and Bowers, M. T. (2012) Aβ(39-42) modulates Aβ oligomerization but not fibril formation, Biochemistry 51, 108-117.
[44] de Groot, N. S., Parella, T., Aviles, F. X., Vendrell, J., and Ventura, S. (2007) Ile-phe dipeptide self-assembly: clues to amyloid formation, Biophys J 92, 1732-1741.
[45] Colvin, M. T., Silvers, R., Frohm, B., Su, Y., Linse, S., and Griffin, R. G. (2015) High resolution structural characterization of Aβ42 amyloid fibrils by MAS NMR, J Am Chem Soc.